BOSTON, Aug. 3, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a women's health therapeutics company, today announced financial results for the three-month period ended June 30, 2017. Cash and cash equivalents were $21.5 million at June 30, 2017, a 1% decrease from March 31, 2017.
